Respiratory tract infection

2 trials MedDRA PT
2 Registered trials
0 Recruiting
2 Unique sponsors
4 Unique IMPs
1 Commercial trials
Drug classes (ATC)
J Anti-infectives (ATC J) 1
R Respiratory (ATC R) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Supportive / diluent 1 substance
Phase II/III: 1 Phase IV: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase II/III

1 trial
  • University Medical Center Utrecht Academic
    NITRIC OXIDE; SODIUM CHLORIDE SOLUTION 0.9%; VOXVOGANAN
    2022-501707-27-01 6 countries 2024 n=911
    Ended

Phase IV

1 trial
  • Lallemand Pharma Europe filial af Lallemand Pharma AG Schweiz Commercial
    HAEMOPHILUS INFLUENZAE, KLEBSIELLA OZAENAE, KLEBSIELLA PNEUMONIAE, NEISSERIA CATARRHALIS, STAPHYLOCOCCUS AUREUS, STREPTOCOCCUS PNEUMONIAE, STREPTOCOCCUS PYOGENES, STREPTOCOCCUS VIRIDANS
    2025-524212-11-00 1 country n=224
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Lallemand Pharma Europe filial af Lallemand Pharma AG Schweiz Commercial 1 Phase IV 0
University Medical Center Utrecht Academic 1 Phase II/III 0
New trials by year
2024
1
← All indication landscapes